Clinical trials: Chikungunya Fever
Dengue Fever
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
Background: Some mosquitos carry viruses that can cause disease. Some examples are dengue and Zika. The mosquitos spread disease by biting people and infecting them with the virus.
- Trial name
- NCT03534245
- Where
- Cambodia
- Volunteers
- 775 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.
- Trial name
- NCT07003984
- Testing
- CHIKV VLP vaccine
- Where
- 15 sites in United States, Philippines and 1 more
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Healthy Adult, Healthy Adolescents
Evaluation of IXCHIQ® Vaccine Immunogenicity
The goal of this clinical trial is to evaluate the quality and duration of the immune response against chikungunya virus elicited by the IXCHIQ® vaccine in healthy adults and adolescents.
- Trial name
- IMUNO-CHIQ (NCT07846293)
- Testing
- IXCHIQ vaccine
- Where
- Brazil
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mauro Martins Teixeira
Chikungunya Virus Infection
Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana
In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and…
- Trial name
- CHIK-RE-VAC (NCT06928753)
- Testing
- IXCHIQ, VIMKUNYA
- Where
- 2 sites in French Guiana, Reunion
- Volunteers
- 1,505 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Chikungunya Virus Infection, Neonatal
Against Chikungunya Virus and Neonatal Infection
The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum…
- Conditions
- Chikungunya Virus Infection, Neonatal, Transfusion, Encephalopathy
- Trial name
- ConvictionCHIK (NCT07190560)
- Testing
- plasma transfusion : PC-CHIK-V
- Where
- 3 sites in France, French Guiana and 1 more
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate…
- Trial name
- NCT06007183
- Testing
- CHIKV VLP vaccine booster
- Where
- 24 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya Virus Infection
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
This is an observational study with primary data collection, which will combine a prospective safety cohort study and an SCRI study.
- Trial name
- NCT07254702
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
VLA1553-403 Pregnancy Surveillance Study
This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last…
- Trial name
- NCT07414524
- Testing
- Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH
- Where
- 3 sites in Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
This is an observational, non-interventional, test-negative case-control (TNCC) study to estimate the vaccine effectiveness of VLA1553 against Chikungunya virus in a real-world setting.
- Trial name
- NCT07347002
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Chikungunya Virus Infection
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
- Trial name
- NCT04838444
- Testing
- VLA1553
- Where
- 10 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site…
- Trial name
- NCT07467707
- Testing
- CHIKV VLP vaccine
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 6,144 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control.
- Trial name
- NCT04650399
- Testing
- Active
- Where
- 10 sites in Brazil
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue, Chikungunya
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance…
- Trial name
- NCT07600879
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade do Estado do Pará
Chikungunya, Chikungunya Fever
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60…
- Conditions
- Chikungunya, Chikungunya Fever, Chikungunya Virus Infection, Chikungunya Virus Infections
- Trial name
- NCT07394426
- Testing
- PepGNP-ChikV
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Active Immunisation for Chikungunya Virus Infection
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
- Trial name
- CHIKV/II-III (NCT07555392)
- Testing
- BBV87 Chikungunya vaccine
- Where
- 10 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Bharat Biotech International Limited
Malaria Fever, Zika
Xpert® Tropical Fever Test on GeneXpert® Edge X System
This is a multi-site, observational, cross-sectional clinical study that includes geographically diverse sites within and outside the United States.
- Conditions
- Malaria Fever, Zika, Dengue Fever, Leptospirosis
- Trial name
- NCT07520279
- Testing
- Xpert Tropical Fever test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Cepheid
Dengue, Zika
Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities
Arboviral diseases such as dengue, Zika, and chikungunya, transmitted by Aedes mosquitoes, remain an important public health concern in Colombian communities.
- Conditions
- Dengue, Zika, Chikungunya, Aedes-borne Diseases
- Trial name
- DigiAedes (NCT07517731)
- Testing
- Full intervention, Partial intervention
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Freiburg